A randomised phase Ii trial studying adjuvant thalidomide for patients at high risk of disease recurrence following surgery for renal cell carcinoma

Trial Profile

A randomised phase Ii trial studying adjuvant thalidomide for patients at high risk of disease recurrence following surgery for renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2009

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2009 Status changed from recruiting to completed.
    • 01 Feb 2009 Primary endpoint 'Disease recurrence rate' has been met.
    • 01 Feb 2009 Status change from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top